Search Videos and More
Video
ESMO25 Breast Cancer Highlights: evERA and SERENA6
Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH, discuss the evERA and SERENA6 trials investigating oral selective estrogen receptor degraders (SERDs).
Video
ESMO25 Breast Cancer Highlights: Antibody-Drug Conjugates
Harold Burstein, MD, PhD, and Ilana Schlam, MD, MPH, discuss OptiTROP-Breast02 and other trials investigating antibody-drug conjugates (ADCs).
Video
ESMO25 Breast Cancer Highlight Recap
Harold Burstein, MD, PhD, summarizes important breakthroughs presented at ESMO 2025 for all sub-types and stages of breast cancer.
Video
ESMO25 Breast Cancer Highlights
Harold Burstein, MD, PhD, and other breast cancer experts at Dana-Farber discuss important breast cancer research presented at ESMO 2025.
News
Dana-Farber Research Opens the Door to Finding More Effective Treatments for Ewing Sarcoma
In 2014, Dana-Farber pediatric oncologist Brian Crompton, MD, discovered that a gene called STAG2 is mutated in about 15 percent of patients with Ewing sarcoma, a form of bone cancer that largely occurs in children and adolescents.
News
Dana-Farber Research Supports FDA Approval of Sevabertinib for HER2-Mutant Lung Cancer
The US Food and Drug Administration has approved sevabertinib, an oral targeted therapy for adult patients with non-small-cell lung cancer (NSCLC) whose tumors harbor certain HER2 (also called ERBB2) mutations and who have previously received chemotherapy or immunotherapy.
Video
2025 ESMO Prostate Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the prostate cancer clinical updates you need to know from ESMO 2025
Video
2025 ESMO Bladder Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the bladder cancer clinical updates you need to know from ESMO 2025.
Video
2025 ESMO Kidney Cancer Highlights
The Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute presents a succinct summary of all the kidney cancer clinical updates you need to know from ESMO 2025.
News
Dana-Farber Research News 11.15.2025
This twice-monthly newsletter highlights recently published research where Dana-Farber faculty are listed as first or senior authors. The information is pulled from PubMed and this issue notes papers published from October 16 - October 31.
Symposium
ESMO Congress 2025
Review video summaries and research highlights from Dana-Farber Faculty, presented at ESMO Congress 2025.
News
Dana-Farber Cancer Institute Faculty Among World's Most Highly Cited Researchers
Dana-Farber Cancer Institute is proud to announce that 38 of its researchers have been named to the Highly Cited Researchers list of 2025, released by the Institute for Scientific Information at Clarivate.